INCY Incyte Genomics Inc Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
06:26
Aug 21
Aug 21
Incyte cheap with high margin growth.
Incyte is cheap at 14-16x earnings with stable revenue from Jakafi, rising EPS, buybacks, 30% operating margin, about 30% sales growth, and DCF value near 140-150.
HIGH
12:58
Aug 17
Aug 17
Reports largest aggregate Q2 fund holdings
"Reports largest aggregate Q2 2026 holdings across 95 specialist funds based on 13F filings, no directional view."
MED
12:31
Aug 17
Aug 17
Notes large aggregate Q2 fund holdings
Notes the stock is among the largest aggregate Q2 holdings across 93 funds based on 13F filings.
MED
11:28
Aug 17
Aug 17
A news wire reports a broad list of price target increases across dozens of stocks from various.
A news wire reports a broad list of price target increases across dozens of stocks from various analysts, with no directional commentary or personal market views expressed.
16:04
Aug 07
Aug 07
Incyte cup-and-handle breakout
Incyte (INCY) is forming a cup-and-handle pattern with accelerating fundamentals, and he expects a breakout to new highs.
MED
17:15
Aug 04
Aug 04
Earnings beat with expanding drug pipeline.
Incyte reported Q4 revenue of $1.67B and adjusted earnings of $3.09, crushing the $2.12 estimate, and raised full-year net sales guidance. The company, once seen as a one-drug name, now has a pipeline of 9–10 drugs in various stages of trials, all of which could be major winners. Technically, traders can watch the $109 area (50-day) as an alert, investors can use the 200-day near $101, with the uptrend over above $100.
HIGH
11:35
Jul 29
Jul 29
Barclays, Jefferies, RBC, JP Morgan, and other firms raised price targets on dozens of stocks.
Barclays, Jefferies, RBC, JP Morgan, and other firms raised price targets on dozens of stocks including ABBV, KO, and F in a broad round of analyst upgrades.
12:00
Jul 28
Jul 28
The overall guidance tone is confident with raised revenue guidance for the year, reflecting broad-based strength across the portfolio and a stronger pipeline.
HIGH
20:12
Jun 19
Jun 19
Speaker cites INCY as actively seeking an immunology acquisition.
Speaker cites INCY as actively seeking an immunology acquisition, flagging NKTR as a potential target; no direct INCY directional view stated.
LOW
15:38
Jun 08
Jun 08
Incyte CEO confirmed the company is actively seeking I&I bolt-on acquisitions.
Incyte CEO confirmed the company is actively seeking I&I bolt-on acquisitions; mentioned as potential acquirer of NKTR, no direct directional view on INCY itself stated.
MED
11:42
Jun 08
Jun 08
Incyte announces agreement to acquire Vega Therapeutics for $1.25 billion to expand its.
Incyte announces agreement to acquire Vega Therapeutics for $1.25 billion to expand its hematology portfolio into bleeding disorders.
12:00
Apr 28
Apr 28
Management conveys strong confidence in the company's trajectory, with net sales up 20%, a strong pipeline, and multiple upcoming regulatory milestones. The tone is optimistic, and they reaffirm full-year guidance while highlighting the potential of new product launches.
HIGH
01:10
Mar 08
Mar 08
The failure to win a key FDA label expansion is a direct negative catalyst for the stock.
The failure to win a key FDA label expansion is a direct negative catalyst for the stock, impacting future revenue streams.
MED
08:24
Feb 20
Feb 20
The trade is long Incyte based on the continued strength of its ruxolitinib franchise.
The trade is long Incyte based on the continued strength of its ruxolitinib franchise and strong expected sales growth for its drug Opzelura.
MED
13:00
Feb 10
Feb 10
Management guided revenues up 10-13% and emphasized multiple late-stage pipeline catalysts (Monjuvi, Povacitinib, KRAS G12D, etc.) that could triple the top line. The long-term strategy to replace the Jackify franchise with diversified core growth underpins the bullish tone.
HIGH
09:20
Jan 24
Jan 24
Long INCY ahead of Phase 2 with 100% ML score.
The author's ML model holds INCY long ahead of a Phase 2 catalyst in 8 days, assigning a 100% confidence score for a positive catalyst outcome. A favorable readout could push the stock toward the $122.95 target; the trade is invalidated below the $98.36 stop loss.
HIGH
23:02
Jan 13
Jan 13
Incyte can offset Jakafi patent cliff.
Bill Meury says Incyte can navigate the 2028 Jakafi patent cliff and replace roughly $3 billion of revenue because its core business is still performing and it has advanced seven prioritized programs supported by 14 Phase 3 trials. Management only needs two or three winners out of the seven programs to offset the cliff, and the pipeline gives investors greater visibility into the growth trajectory and breadth/depth of the business.
HIGH
01:48
Jan 10
Jan 10
Incyte valuation too good; buybacks and diversification support adding.
The author already owns Incyte and is considering buying more because the valuation is too good. The company is diversifying beyond Jakafi, has insider buybacks, low debt, sector-outperforming growth, and excellent margins. His general holding preference is at least 3 years; no specific risk is stated.
HIGH
01:42
Jan 10
Jan 10
Incyte valuation too good; buybacks and diversification support adding.
The author already owns Incyte and is considering buying more because the valuation is too good. The company is diversifying beyond Jakafi, has insider buybacks, low debt, sector-outperforming growth, and excellent margins. His general holding preference is at least 3 years; no specific risk is stated.
HIGH
About INCY Investor Commentary
Across the available history and selected sources, Buzzberg tracks INCY (Incyte Genomics Inc) across 11 sources: 7 bullish vs 0 bearish calls from 11 authors. Historical directional balance: 35% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 20 total trade ideas tracked. Latest voices: Гоша, seedy19tron, DeItaone.